Search

Your search keyword '"Portlock, Carol"' showing total 570 results
Start Over Author "Portlock, Carol"
570 results on '"Portlock, Carol"'

1. Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP

Author

Bantilan, Kurt S., Smith, Alexandra N., Maurer, Matthew J., Teruya-Feldstein, Julie, Matasar, Matthew J., Moskowitz, Alison J., Straus, David J., Noy, Ariela, Palomba, M. Lia, Horwitz, Steven M., Hamlin, Paul A., Portlock, Carol S., Cerhan, James R., Habermann, Thomas M., Salles, Gilles A., Nowakowski, Grzegorz S., Moskowitz, Craig H., and Zelenetz, Andrew D.

Published
2024
Full Text
View/download PDF

4. A genome-wide association study of marginal zone lymphoma shows association to the HLA region.

Author

Vijai, Joseph, Wang, Zhaoming, Berndt, Sonja I, Skibola, Christine F, Slager, Susan L, de Sanjose, Silvia, Melbye, Mads, Glimelius, Bengt, Bracci, Paige M, Conde, Lucia, Birmann, Brenda M, Wang, Sophia S, Brooks-Wilson, Angela R, Lan, Qing, de Bakker, Paul IW, Vermeulen, Roel CH, Portlock, Carol, Ansell, Stephen M, Link, Brian K, Riby, Jacques, North, Kari E, Gu, Jian, Hjalgrim, Henrik, Cozen, Wendy, Becker, Nikolaus, Teras, Lauren R, Spinelli, John J, Turner, Jenny, Zhang, Yawei, Purdue, Mark P, Giles, Graham G, Kelly, Rachel S, Zeleniuch-Jacquotte, Anne, Ennas, Maria Grazia, Monnereau, Alain, Bertrand, Kimberly A, Albanes, Demetrius, Lightfoot, Tracy, Yeager, Meredith, Chung, Charles C, Burdett, Laurie, Hutchinson, Amy, Lawrence, Charles, Montalvan, Rebecca, Liang, Liming, Huang, Jinyan, Ma, Baoshan, Villano, Danylo J, Maria, Ann, Corines, Marina, Thomas, Tinu, Novak, Anne J, Dogan, Ahmet, Liebow, Mark, Thompson, Carrie A, Witzig, Thomas E, Habermann, Thomas M, Weiner, George J, Smith, Martyn T, Holly, Elizabeth A, Jackson, Rebecca D, Tinker, Lesley F, Ye, Yuanqing, Adami, Hans-Olov, Smedby, Karin E, De Roos, Anneclaire J, Hartge, Patricia, Morton, Lindsay M, Severson, Richard K, Benavente, Yolanda, Boffetta, Paolo, Brennan, Paul, Foretova, Lenka, Maynadie, Marc, McKay, James, Staines, Anthony, Diver, W Ryan, Vajdic, Claire M, Armstrong, Bruce K, Kricker, Anne, Zheng, Tongzhang, Holford, Theodore R, Severi, Gianluca, Vineis, Paolo, Ferri, Giovanni M, Ricco, Rosalia, Miligi, Lucia, Clavel, Jacqueline, Giovannucci, Edward, Kraft, Peter, Virtamo, Jarmo, Smith, Alex, Kane, Eleanor, Roman, Eve, Chiu, Brian CH, Fraumeni, Joseph F, Wu, Xifeng, Cerhan, James R, Offit, Kenneth, and Chanock, Stephen J

Subjects
Humans, Membrane Glycoproteins, Computational Biology, Major Histocompatibility Complex, Genotype, Polymorphism, Single Nucleotide, European Continental Ancestry Group, Lymphoma, B-Cell, Marginal Zone, Genome-Wide Association Study, Butyrophilins, Polymorphism, Single Nucleotide, Lymphoma, B-Cell, Marginal Zone
Abstract

Marginal zone lymphoma (MZL) is the third most common subtype of B-cell non-Hodgkin lymphoma. Here we perform a two-stage GWAS of 1,281 MZL cases and 7,127 controls of European ancestry and identify two independent loci near BTNL2 (rs9461741, P=3.95 × 10(-15)) and HLA-B (rs2922994, P=2.43 × 10(-9)) in the HLA region significantly associated with MZL risk. This is the first evidence that genetic variation in the major histocompatibility complex influences MZL susceptibility.

Published
2015

5. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma

Author

Moskowitz, Alison J., Schöder, Heiko, Gavane, Somali, Thoren, Katie L., Fleisher, Martin, Yahalom, Joachim, McCall, Susan J., Cadzin, Briana R., Fox, Stephanie Y., Gerecitano, John, Grewal, Ravinder, Hamlin, Paul A., Horwitz, Steven M., Kumar, Anita, Matasar, Matthew, Ni, Andy, Noy, Ariela, Palomba, M. Lia, Perales, Miguel-Angel, Portlock, Carol S., Sauter, Craig, Straus, David, Younes, Anas, Zelenetz, Andrew D., and Moskowitz, Craig H.

Published
2017
Full Text
View/download PDF

6. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

Author

Kumar, Anita, Casulo, Carla, Yahalom, Joachim, Schöder, Heiko, Barr, Paul M., Caron, Philip, Chiu, April, Constine, Louis S., Drullinsky, Pamela, Friedberg, Jonathan W., Gerecitano, John F., Hamilton, Audrey, Hamlin, Paul A., Horwitz, Steven M., Jacob, Alexandra G., Matasar, Matthew J., McArthur, Gianna N., McCall, Susan J., Moskowitz, Alison J., Noy, Ariela, Palomba, Maria L., Portlock, Carol S., Straus, David J., VanderEls, Nicholas, Verwys, Stephanie L., Yang, Joanna, Younes, Anas, Zelenetz, Andrew D., Zhang, Zhigang, and Moskowitz, Craig H.

Published
2016
Full Text
View/download PDF

7. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse

Author

Kumar, Anita, Sha, Fushen, Toure, Ahmed, Dogan, Ahmet, Ni, Andy, Batlevi, Connie L., Palomba, Maria Lia M., Portlock, Carol, Straus, David J., Noy, Ariela, Horwitz, Steven M., Moskowitz, Alison, Hamlin, Paul, Moskowitz, Craig H., Matasar, Matthew J., Zelenetz, Andrew D., and Younes, Anas

Published
2019
Full Text
View/download PDF

8. Supplementary Figure Legends from The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

Author

Soumerai, Jacob D., primary, Zelenetz, Andrew D., primary, Moskowitz, Craig H., primary, Palomba, M. Lia, primary, Hamlin, Paul A., primary, Noy, Ariela, primary, Straus, David J., primary, Moskowitz, Alison J., primary, Younes, Anas, primary, Matasar, Matthew J., primary, Horwitz, Steven M., primary, Portlock, Carol S., primary, Konner, Jason A., primary, Gounder, Mrinal M., primary, Hyman, David M., primary, Voss, Martin H., primary, Fury, Matthew G., primary, Gajria, Devika, primary, Carvajal, Richard D., primary, Ho, Alan L., primary, Beumer, Jan H., primary, Kiesel, Brian, primary, Zhang, Zhigang, primary, Chen, Alice, primary, Little, Richard F., primary, Jarjies, Christine, primary, Dang, Thu O., primary, France, Fallon, primary, Mishra, Nishant, primary, and Gerecitano, John F., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure S1 from The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

Author

Soumerai, Jacob D., primary, Zelenetz, Andrew D., primary, Moskowitz, Craig H., primary, Palomba, M. Lia, primary, Hamlin, Paul A., primary, Noy, Ariela, primary, Straus, David J., primary, Moskowitz, Alison J., primary, Younes, Anas, primary, Matasar, Matthew J., primary, Horwitz, Steven M., primary, Portlock, Carol S., primary, Konner, Jason A., primary, Gounder, Mrinal M., primary, Hyman, David M., primary, Voss, Martin H., primary, Fury, Matthew G., primary, Gajria, Devika, primary, Carvajal, Richard D., primary, Ho, Alan L., primary, Beumer, Jan H., primary, Kiesel, Brian, primary, Zhang, Zhigang, primary, Chen, Alice, primary, Little, Richard F., primary, Jarjies, Christine, primary, Dang, Thu O., primary, France, Fallon, primary, Mishra, Nishant, primary, and Gerecitano, John F., primary

Published
2023
Full Text
View/download PDF

11. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

Author

Moskowitz, Alison J, Schöder, Heiko, Yahalom, Joachim, McCall, Susan J, Fox, Stephanie Y, Gerecitano, John, Grewal, Ravinder, Hamlin, Paul A, Horwitz, Steven, Kobos, Rachel, Kumar, Anita, Matasar, Matthew, Noy, Ariela, Palomba, M Lia, Perales, Miguel-Angel, Portlock, Carol S, Sauter, Craig, Shukla, Neerav, Steinherz, Peter, Straus, David, Trippett, Tanya, Younes, Anas, Zelenetz, Andrew, and Moskowitz, Craig H

Published
2015
Full Text
View/download PDF

13. Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay

Author

Intlekofer, Andrew M., Joffe, Erel, Batlevi, Connie L., Hilden, Patrick, He, Jie, Seshan, Venkatraman E., Zelenetz, Andrew D., Palomba, M. Lia, Moskowitz, Craig H., Portlock, Carol, Straus, David J., Noy, Ariela, Horwitz, Steven M., Gerecitano, John F., Moskowitz, Alison, Hamlin, Paul, Matasar, Matthew J, Kumar, Anita, van den Brink, Marcel R., Knapp, Kristina M., Pichardo, Janine D., Nahas, Michelle K., Trabucco, Sally E., Mughal, Tariq, Copeland, Amanda R., Papaemmanuil, Elli, Moarii, Mathai, Levine, Ross L., Dogan, Ahmet, Miller, Vincent A., and Younes, Anas

Published
2018
Full Text
View/download PDF

17. Normalization of pre-ASCT, FDG-PET imaging with second-line, non–cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

Author

Moskowitz, Craig H., Matasar, Matt J., Zelenetz, Andrew D., Nimer, Stephen D., Gerecitano, John, Hamlin, Paul, Horwitz, Steven, Moskowitz, Alison J., Noy, Ariela, Palomba, Lia, Perales, Miguel-Angel, Portlock, Carol, Straus, David, Maragulia, Jocelyn C., Schoder, Heiko, and Yahalom, Joachim

Published
2012
Full Text
View/download PDF

27. Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

Author

Kumar, Anita, primary, Westin, Jason, additional, Schuster, Stephen J, additional, Nowakowski, Grzegorz S., additional, Lossos, Izidore S., additional, Batlevi, Connie Lee, additional, Caron, Philip, additional, Drullinsky, Pamela, additional, Gerecitano, John, additional, Hamilton, Audrey, additional, Hamlin, Paul A., additional, Horwitz, Steven M., additional, Jacob, Allison P., additional, Joffe, Erel, additional, Joseph, Ashlee, additional, von Keudell, Gottfried R., additional, Laraque, Leana, additional, Lahoud, Oscar B, additional, Matasar, Matthew J, additional, Moskowitz, Craig H., additional, Mullins, Chelsea D, additional, Noy, Ariela, additional, Owens, Colette, additional, Palomba, Maria Lia, additional, Portlock, Carol S., additional, Rodriguez-Rivera, Ildefonso, additional, Salles, Gilles, additional, Seshan, Venkatraman, additional, Straus, David J., additional, Vemuri, Shreya, additional, Younes, Anas, additional, and Zelenetz, Andrew D, additional

Published
2020
Full Text
View/download PDF

28. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging

Author

Moskowitz, Craig H., Yahalom, Joachim, Zelenetz, Andrew D., Zhang, Zhigang, Filippa, Daniel, Teruya-Feldstein, Julie, Kewalramani, Tarun, Moskowitz, Alison J., Rice, Robert David, Maragulia, Jocelyn, Vanak, Jill, Trippett, Tanya, Hamlin, Paul, Horowitz, Steven, Noy, Ariela, OʼConnor, Owen A., Portlock, Carol, Straus, David, and Nimer, Stephen D.

Published
2010
Full Text
View/download PDF

31. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma

Author

OʼConnor, Owen A., Hamlin, Paul A., Portlock, Carol, Moskowitz, Craig H., Noy, Ariela, Straus, David J., MacGregor-Cortelli, Barbara, Neylon, Ellen, Sarasohn, Debra, Dumetrescu, Otila, Mould, Diane R., Fleischer, Martin, Zelenetz, Andrew D., Sirotnak, Frank, and Horwitz, Steven

Published
2007

33. Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies

Author

OʼConnor, Owen A., Heaney, Mark L., Schwartz, Lawrence, Richardson, Stacie, Willim, Robert, MacGregor-Cortelli, Barbara, Curly, Tracey, Moskowitz, Craig, Portlock, Carol, Horwitz, Steven, Zelenetz, Andrew D., Frankel, Stanley, Richon, Victoria, Marks, Paul, and Kelly, William K.

Published
2006
Full Text
View/download PDF

40. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma

Author

Borchmann, Sven, Joffe, Erel, Moskowitz, Craig H., Zelenetz, Andrew D., Noy, Ariela, Portlock, Carol S., Gerecitano, John F., Batlevi, Connie L., Caron, Philip C., Drullinsky, Pamela, Hamilton, Audrey, Hamlin, Paul A., Jr., Horwitz, Steven M., Kumar, Anita, Matasar, Matthew J., Moskowitz, Alison J., Owens, Colette N., Palomba, M. Lia, Younes, Anas, Straus, David J., Borchmann, Sven, Joffe, Erel, Moskowitz, Craig H., Zelenetz, Andrew D., Noy, Ariela, Portlock, Carol S., Gerecitano, John F., Batlevi, Connie L., Caron, Philip C., Drullinsky, Pamela, Hamilton, Audrey, Hamlin, Paul A., Jr., Horwitz, Steven M., Kumar, Anita, Matasar, Matthew J., Moskowitz, Alison J., Owens, Colette N., Palomba, M. Lia, Younes, Anas, and Straus, David J.

Abstract

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of lymphoma that, like other Hodgkin lymphomas, has historically been treated aggressively. However, in most cases, NLPHL has an indolent course, which raises the question of to what extent these patients require aggressive upfront treatment. We describe the management and outcomes of consecutive NLPHL patients diagnosed at Memorial Sloan Kettering Cancer Center (MSK), with a focus on evaluating active surveillance. All patients aged 16 years or older diagnosed and followed at MSK between 1974 and 2016 were included. Treatment outcomes were compared between management with active surveillance and other strategies. We identified 163 consecutive patients who were treated with radiotherapy alone (46%), active surveillance (23%), chemotherapy (16%), combined modality (12%), or rituximab monotherapy (4%). Median follow-up was 69 months. Five-year progression-free survival (PFS), second PFS (PFS2), and overall survival (OS) estimates were 85% (95% confidence interval [CI], 78-90), 97% (95% CI, 92-99), and 99% (95% CI, 95-100), respectively. Only 1 of 7 deaths was lymphoma related. Patients managed with active surveillance had slightly shorter PFS than those receiving any active treatment, with 5-year PFS of 77%(95% CI, 56-89) vs 87%(95% CI, 79-92; P = .017). This difference did not translate into better PFS2 or OS. Only 10 patients managed with active surveillance (27%) eventually required treatment, after a median of 61 months, and none died. NLPHL has an excellent prognosis. Within the limitations of a retrospective analysis, active surveillance is a viable initial management strategy for selected NLPHL patients.

Published
2019

44. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma

Author

Offit, Kenneth, Lo Coco, Francesco, Louie, Diane C., Parsa, Nasser Z., Leung, Denis, Portlock, Carol, Ye, Bihui H., Lista, Florigio, Filippa, Daniel A., Rosenbaum, Ayala, Ladanyi, Marc, Jhanwar, Suresh, Dalla-Favera, Riccardo, and Chaganti, R.S.K.

Subjects
Non-Hodgkin's lymphomas -- Prognosis, Translocation (Genetics) -- Health aspects
Abstract

Rearranged bcl-6 genes appear to be associated with a better prognosis in patients with a type of non-Hodgkin's lymphoma known as diffuse large-cell lymphoma (DLLC). Bcl-6 is a potentially cancer-inducing gene. Genetic analysis was performed on lymphoma samples from 102 patients with DLLC. Twenty-three patients had rearranged bcl-6 and 21 had rearranged bcl-2. There was no evidence of either bcl-6 or bcl-2 rearrangement in the remaining 58 samples. Patients without rearranged bcl-6 genes were more likely to have more severe disease with bone marrow involvement. Patients with bcl-6 rearrangement were less likely to develop bone marrow involvement. Eighty-two percent of patients with rearranged bcl-6 were predicted to be alive 36 months after diagnosis compared with 56% of patients without bcl-6 rearrangement.

Published
1994

46. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated burkitt lymphoma

Author

Wang, Eunice S., Straus, David J., Teruya-Feldstein, Julie, Qin, Jing, Portlock, Carol, Moskowitz, Craig, Goy, Andre, Hedrick, Eric, Zelenetz, Andrew D., and Noy, Ariela

Subjects
Chemotherapy -- Methods, Chemotherapy -- Usage, HIV (Viruses) -- Risk factors, HIV (Viruses) -- Care and treatment, Burkitt's lymphoma -- Risk factors, Health
Published
2003

49. Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)

Author

Leyfman, Yan, primary, Joffe, Erel, additional, Drill, Esther, additional, Rajeeve, Sridevi, additional, Zelenetz, Andrew D., additional, Palomba, Maria Lia Lia, additional, Moskowitz, Craig H., additional, Portlock, Carol S., additional, Noy, Ariela, additional, Horwitz, Steven M., additional, Moskowitz, Alison J., additional, Hamlin, Paul A., additional, Matasar, Matthew J, additional, Kumar, Anita, additional, von Keudell, Gottfried R., additional, Batlevi, Connie Lee, additional, Younes, Anas, additional, and Straus, David J., additional

Published
2019
Full Text
View/download PDF

50. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma

Author

Borchmann, Sven, primary, Joffe, Erel, additional, Moskowitz, Craig H., additional, Zelenetz, Andrew D., additional, Noy, Ariela, additional, Portlock, Carol S., additional, Gerecitano, John F., additional, Batlevi, Connie L., additional, Caron, Philip C., additional, Drullinsky, Pamela, additional, Hamilton, Audrey, additional, Hamlin, Paul A., additional, Horwitz, Steven M., additional, Kumar, Anita, additional, Matasar, Matthew J., additional, Moskowitz, Alison J., additional, Owens, Colette N., additional, Palomba, M. Lia, additional, Younes, Anas, additional, and Straus, David J., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results